| Document and Entity Information | May 16, 2024 |
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001327273 |
| Document Type | 8-K/A |
| Document Period End Date | May 16, 2024 |
| Entity Registrant Name | Lyra Therapeutics, Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-39273 |
| Entity Tax Identification Number | 84-1700838 |
| Entity Address, Address Line One | 480 Arsenal Way |
| Entity Address, City or Town | Watertown |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02472 |
| City Area Code | 617 |
| Local Phone Number | 393-4600 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.001 par value per share |
| Trading Symbol | LYRA |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Amendment Description | This Current Report on Form 8-K/A (the “Current Report”) amends the Current Report on Form 8-K filed by Lyra Therapeutics, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on May 21, 2024 (the “Original Report”) and is being filed solely in order to amend and supplement the Company’s disclosure contained in Item 2.05 of the Original Report. The Original Report otherwise remains unchanged. |
